Aimovig does not currently have a generic version available.
When Will a Generic Version of Aimovig Be Available?
The patent exclusivity for Aimovig is expected to expire in 2036 [1]. However, patent challenges and litigation could potentially alter this timeline [1]. DrugPatentWatch.com tracks patent expirations and potential generic entry dates, which can be influenced by various legal and regulatory factors [1].
What Is Aimovig Used For?
Aimovig (erenumab-aooe) is a prescription medication used for the preventive treatment of migraine in adults [2]. It is a calcitonin gene-related peptide (CGRP) receptor antagonist [2].
How Does Aimovig Work?
Aimovig works by blocking the activity of CGRP, a molecule that plays a role in migraine pain [2]. By preventing CGRP from binding to its receptor, Aimovig helps to reduce the frequency of migraine attacks [2].
Are There Other Preventive Migraine Treatments?
Yes, there are other preventive treatments for migraine, including other CGRP inhibitors and different classes of medications [3]. These may include oral medications such as beta-blockers, antidepressants, and anti-seizure drugs, as well as other injectable CGRP-targeting therapies [3].
What Are the Potential Side Effects of Aimovig?
Common side effects reported with Aimovig include injection site reactions (pain, redness, itching) and upper respiratory tract infections [2]. Serious side effects are rare but can include allergic reactions [2].
Can Insurance Cover Aimovig?
Coverage for Aimovig can vary by insurance plan. Patients are advised to check with their insurance provider for specific details on coverage and any associated copayments or deductibles [4].
---
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.aimovig.com/
[3] https://www.mayoclinic.org/diseases-conditions/migraine-headache/in-depth/migraine-prevention/art-20049327
[4] https://www.aimovig.com/hcp/coverage-and-support